ARDT Stock Forecast & Price Target

Ardent Health is well positioned because its 2Q26 adjusted EBITDA beat expectations on a successful payer contract renegotiation and faster IMPACT savings, which more than offset temporary surgical volume softness. Its 2026 outlook remains constructive with revenue guidance of $6.4B-$6.7B and EBITDA guidance of $485M-$535M, supported by an expected $15M-$20M of incremental IMPACT benefits, $5M-$10M from the New Mexico contract reset, and a manageable ~$35M HIX headwind. The company also has attractive long-term fundamentals, including leading share in mid-sized urban markets, a stronger balance sheet, lower contract labor costs, stable denial trends, and growth opportunities from outpatient expansion and its differentiated joint venture strategy.

Ardent Health is viewed negatively because its core volume trends remain soft, with 2Q26 surgeries down 2.9% y/y, admissions down 1.0% y/y, and April-May activity even weaker before only modest improvement in June and July. Although management raised 2026 IMPACT savings to at least $70MM and expects $20-30MM of incremental EBITDA, those benefits mostly offset about $25MM of volume-related earnings pressure, leaving limited net resilience. Inpatient surgeries fell 7.5%, and while the net economic impact of inpatient-only list changes was modest at $1M-$2M, the broader downside case highlights execution risk if ambulatory expansion, organic volume growth, or payer, labor, and reimbursement conditions fail to improve.